JAK2 and Miyoshi myopathy: The purpose of this study was to evaluate whether the potential anticancer effects of radotinib, as known a tyrosine kinase inhibitor, in MM was mediated primarily through blockade of the STAT3 and JAK2 signaling pathway in vitro and in vivo.